Patrick Lamy - 31 Dec 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
31 Dec 2024
Net transactions value
-$201,063
Form type
4
Filing time
29 Jan 2025, 20:43:28 UTC
Previous filing
18 Dec 2024
Next filing
05 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $4,607 +234 +0.68% $19.69 34,492 31 Dec 2024 Direct F1, F2
transaction AKRO Common Stock Options Exercise $79,480 +4,000 +12% $19.87 38,492 27 Jan 2025 Direct F3
transaction AKRO Common Stock Sale $285,150 -5,000 -13% $57.03 33,492 27 Jan 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -4,000 -4.8% $0.000000 79,182 27 Jan 2025 Common Stock 83,182 $19.87 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Mr. Lamy is voluntarily reporting the acquisition of these shares on December 31, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on July 1, 2024.
F3 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 28, 2024, previously adopted by the Reporting Person.
F4 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.